Christopher Haqq

2023 - Elicio Therapeutics

In 2023, Christopher Haqq earned a total compensation of $673.8K as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics, a 42% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$185,545
Salary$488,276
Total$673,821

Haqq received $488.3K in salary, accounting for 72% of the total pay in 2023.

Haqq also received $185.5K in non-equity incentive plan.

Rankings

In 2023, Christopher Haqq's compensation ranked 1,671st out of 2,983 executives tracked by ExecPay. In other words, Haqq earned more than 44.0% of executives.

ClassificationRankingPercentile
All
1,671
out of 2,983
44th
Division
Manufacturing
971
out of 1,637
41st
Major group
Chemicals And Allied Products
619
out of 906
32nd
Industry group
Drugs
603
out of 869
31st
Industry
Pharmaceutical Preparations
429
out of 627
32nd
Source: SEC filing on September 27, 2024.

Haqq's colleagues

We found four more compensation records of executives who worked with Christopher Haqq at Elicio Therapeutics in 2023.

2023

Jay Venkatesan

Elicio Therapeutics

Chief Executive Officer

2023

Jennifer Rhodes

Elicio Therapeutics

General Counsel

2023

Brian Piekos

Elicio Therapeutics

Chief Financial Officer

2023

Robert Connelly

Elicio Therapeutics

Chief Executive Officer

News

You may also like